ENB Therapeutics is developing platform oncology molecules to unlock the full therapeutic potential of immune-based cancer therapies, specifically targeting the endothelin B receptor (ETBR) to enhance the efficacy of immunotherapies in treating drug-resistant cancers
ENB Therapeutics is developing platform oncology molecules to unlock the full therapeutic potential of immune-based cancer therapies, specifically targeting the endothelin B receptor (ETBR) to enhance the efficacy of immunotherapies in treating drug-resistant cancers.